The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI
Megan Garland, Andrew J. Hryckowian, Martina Tholen, Kristina Oresic Bender, William W. Van Treuren, Sebastian Loscher, Justin L. Sonnenburg, Matthew Bogyo
Abstract
-infected mice. This increased microbiome recovery upon ebselen treatment correlates with a decrease in host-derived inflammatory markers, suggesting that the anti-inflammatory properties of ebselen, combined with its anti-toxin function, help to mitigate the major clinical challenges of CDI, including recurrence, microbial dysbiosis, and colitis.
Topics & Concepts
MicrobiomeEbselenDrugAntibioticsInflammationMedicinePharmacologyIntensive care medicineImmunologyBioinformaticsInternal medicineMicrobiologyOxidative stressBiologyGlutathione peroxidaseCatalaseClostridium difficile and Clostridium perfringens researchGut microbiota and healthAdolescent and Pediatric Healthcare